首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

放射性藥物市場規模、佔有率和成長分析（按類型、適應症、系統、應用、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1899230

放射性藥物市場規模、佔有率和成長分析（按類型、適應症、系統、應用、最終用戶和地區分類）—2026-2033年產業預測

Radiopharmaceuticals Market Size, Share, and Growth Analysis, By Type (Fluorine-18 Derivatives, Technetium-99), By Indication (Diagnosis, Cardiology), By System, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 210 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，放射性藥物市場規模將達到 69.7 億美元，到 2025 年將達到 72.1 億美元，到 2033 年將達到 94.2 億美元，在預測期（2026-2033 年）內複合年成長率為 3.4%。

放射性藥物市場分析顯示，PET和SPECT等影像技術的進步正在提升醫療保健領域的診斷能力。這些技術利用放射性藥物來補充CT和MRI等傳統影像方式，提高其特異性和敏感度。高效放射性示蹤劑的研發顯著提高了診斷準確性，使得癌症、阿茲海默症和心臟病等慢性疾病的早期發現和更詳細的特徵分析成為可能。這些疾病，尤其是男性前列腺癌的日益普遍，凸顯了對先進診斷解決方案日益成長的需求。隨著人口老化和慢性病發病率的上升，放射性藥物市場預計將顯著成長，為參與患者診斷和治療的利害關係人帶來盈利的機會。

全球放射性藥物市場按類型、適應症、系統、應用、最終用戶和地區進行細分。依成分分類，可分為氟-18衍生物、Technetium-99、鎦-177、鎵-68、鋯-89和其他放射性藥物。依適應症分類，可分為診斷、心臟病學和其他適應症。依系統分類，可分為PET和SPECT。依應用分類，可分為腫瘤學、心臟病學、胃腸病學、神經內分泌學、神經病學、腎臟病學和其他應用。依最終用戶分類，可分為醫院、診斷檢查室和其他最終用戶。按地區分類，可分為北美、歐洲、亞太地區、中東和非洲以及拉丁美洲。

放射性藥物市場成長要素

全球癌症患者數量的不斷成長顯著推動了對放射性藥物的需求。這些特殊化合物在標靶治療和診斷中發揮著至關重要的作用，能夠精準定位腫瘤並最大限度地減少副作用。隨著越來越多的人尋求有效的癌症治療方法，他們越來越依賴放射性藥物。這種對個人化癌症治療日益成長的關注，促使醫療服務提供者和患者都優先考慮能夠改善治療效果和提高患者生活品質的創新解決方案，從而推動了市場的持續擴張。這種情況導致了放射性藥物市場的顯著成長。

放射性藥物市場限制因素

由於嚴格的法規結構約束放射性藥物的生產和核准，該市場面臨許多限制因素。製造商在遵守嚴格的安全和品質標準方面面臨許多挑戰，這可能導致漫長的核准流程。這些監管壁壘不僅使業內企業的經營環境複雜化，也限制了它們的擴張和創新能力。因此，這種環境可能阻礙市場成長，並阻礙潛在的新進者，最終影響整個放射性藥物產業的發展，並限制患者治療方案的進步。

放射性藥物市場趨勢

放射性藥物市場正經歷著向個人化醫療的顯著轉變，即根據每位患者獨特的基因譜和疾病特徵量身定做治療方法。這種轉變提高了治療效果，尤其是在腫瘤學和心臟病學等精準治療至關重要的領域。因此，越來越多的投資和興趣投入研發能夠提供標靶治療效果、最大限度提高患者療效並最大限度降低副作用的放射性藥物上。這一發展趨勢與更廣泛的醫療保健趨勢相符，即專注於個人化治療方案，凸顯了個人化解決方案在改善患者預後和推動市場成長方面的重要性。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Cardinal Health（US）
Novartis Company（Switzerland）
Lantheus（US）
Curium（France）
GE HealthCare（US）
Jubilant Pharma Company（India）
China Isotope & Radiation Corporation（China）
Siemens Healthcare GmbH（Germany）
Bracco（Italy）
NTP（South Africa）
Eckert & Ziegler（Germany）
SHINE Technologies, LLC（US）
EczacIbasI-Monrol（Turkey）
IBA Worldwide（Belgium）
Global Medical Solutions（US）
BWX Technologies, Inc.（US）
Institute of Isotopes（Hungary）
Coqui Radiopharmaceuticals Corp.（US）
Evergreen Theragnostics, Inc.（US）
Isotope JSC（Russia）
PharmaLogic Holdings Corp.（US）

簡介目錄

Product Code: SQMIG35H2263

Radiopharmaceuticals Market size was valued at USD 6.97 Billion in 2024 and is poised to grow from USD 7.21 Billion in 2025 to USD 9.42 Billion by 2033, growing at a CAGR of 3.4% during the forecast period (2026-2033).

Market insights into the radiopharmaceuticals sector reveal that advancements in imaging technologies like PET and SPECT are enhancing diagnostic capabilities within healthcare. These modalities utilize radiopharmaceuticals to provide improved specificity and sensitivity, complementing traditional imaging methods such as CT and MRI. The rising development of effective radiotracers has significantly boosted diagnostic accuracy, leading to earlier detection and better characterization of chronic diseases, including cancer, Alzheimer's disease, and heart disease. The increasing prevalence of these conditions, particularly prostate cancer among men, highlights a growing demand for advanced diagnostic solutions. As the population ages and chronic disease rates continue to climb, the radiopharmaceuticals market is poised for significant growth, presenting lucrative opportunities for stakeholders involved in patient diagnosis and treatment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Radiopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Radiopharmaceuticals Market Segments Analysis

Global Radiopharmaceuticals Market is segmented on the type, indication, system, application, end user, and region. By component, market is segmented into fluorine-18 derivatives, technetium-99, lutetium (Lu) 177, gallium-68, zirconium-89, and others. By indication, market is segmented into diagnosis, cardiology, and others. By system, market is segmented into PET, and SPECT. By Application, the market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others. By end user, market is segmented into Hospitals, Diagnostic Labs, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Radiopharmaceuticals Market

The rising prevalence of cancer globally has significantly boosted the demand for radiopharmaceuticals. These specialized compounds play a crucial role in targeted and diagnostic cancer treatments, enabling precise tumor localization while minimizing adverse effects. As more individuals seek effective therapies for cancer management, the reliance on radiopharmaceuticals is becoming increasingly prominent. This heightened focus on tailored cancer care contributes to the ongoing expansion of the market, as healthcare providers and patients alike prioritize innovative solutions that enhance therapeutic outcomes and improve quality of life for those battling the disease. As such, the radiopharmaceuticals market is experiencing substantial growth.

Restraints in the Radiopharmaceuticals Market

The radiopharmaceuticals market faces significant constraints due to a stringent regulatory framework that governs their production and approval. Manufacturers encounter numerous challenges in adhering to rigorous safety and quality standards, which can lead to protracted approval processes. These regulatory hurdles not only complicate the operational landscape for companies within the industry but also restrict their ability to expand and innovate. Consequently, this environment creates barriers to market growth and may deter potential entrants, ultimately impacting the overall development of the radiopharmaceuticals sector and limiting advancements in therapeutic options for patients.

Market Trends of the Radiopharmaceuticals Market

The radiopharmaceuticals market is witnessing a pronounced trend towards personalized medicine, where treatments are specifically designed to cater to the unique genetic profiles and disease characteristics of individual patients. This shift enhances the efficacy of therapies, particularly in oncology and cardiology, where precision is paramount. As a result, there is a growing investment and interest in the development of radiopharmaceuticals that deliver targeted therapeutic outcomes, minimizing side effects and maximizing patient response. This evolution aligns with the broader healthcare focus on customized treatment approaches, underscoring the importance of tailored solutions in improving patient outcomes and driving market growth.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Patent Analysis
Regulatory Landscape
Technological Landscape
PESTEL Analysis
Value Chain Analysis
Supply Chain Analysis

Radiopharmaceuticals Market, By Type

Market Overview
Fluorine-18 Derivatives
- Fluorine-18 Fludeoxyglucose (FDG)
- Fluorine-18 Sodium Fluoride
- Fluorine-18 Flucicovine
- Fluorine-18 Florbetapir
- Fluorine-18 Florbetaben
- Others
Technetium-99
Lutetium (Lu) 177
Gallium-68
- Dotatate
- Dotatoc
Zirconium 89
- 11C-choline
- 14C-urea
Others

Radiopharmaceuticals Market, By Indication

Market Overview
Diagnosis
- Neurology
- Neurodegenerative Disease (AD, PD, and Others)
- Epilepsy
Cardiology
Others

Radiopharmaceuticals Market, By System

Market Overview
PET
- Standalone PET systems
- Hybrid PET/CT
- Hybrid PET/MRI
SPECT

Radiopharmaceuticals Market, By Application

Market Overview
Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others

Radiopharmaceuticals Market, By End User

Market Overview
Hospitals
Diagnostic Labs
Others

Radiopharmaceuticals Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Cardinal Health (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis Company (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE HealthCare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharma Company (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Isotope & Radiation Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthcare GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NTP (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eckert & Ziegler (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SHINE Technologies, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EczacIbasI-Monrol (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IBA Worldwide (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Medical Solutions (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BWX Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Institute of Isotopes (Hungary)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coqui Radiopharmaceuticals Corp. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evergreen Theragnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Isotope JSC (Russia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PharmaLogic Holdings Corp. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments